LILRB1
LILRB1 (leukocyte immunoglobulin-like receptor subfamily B member 1, also known as LIR-1, ILT2, CD85j, MIR-7, CD85, LIR1, PIRB and PIR-B) is an inhibitory receptor for class I MHC antigens. Its engagement dampens immune responses and helps limit autoreactivity. Browse Assay Genie's current range of LILRB1 research reagents below, or read on for the biology behind the target.
LILRB1 is a receptor for class I MHC antigens and recognises a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. It also binds H301/UL18, a human cytomegalovirus class I MHC homologue. Ligand binding produces inhibitory signals and down-regulation of the immune response. When LILRB1 on natural killer cells or T-cells is engaged by class I MHC molecules, the target cells are protected from lysis.
The receptor also acts in other immune contexts. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signalling and serotonin release, and LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilisation of intracellular calcium ions. It recognises HLA-G in complex with B2M (beta-2 microglobulin) and a nonamer self-peptide; on decidual NK cells this interaction triggers secretion of growth-promoting factors. LILRB1 can also reprogramme B cells toward an immune suppressive phenotype.
The LILRB1 gene belongs to the leukocyte immunoglobulin-like receptor (LIR) family, found in a gene cluster at chromosomal region 19q13.4. The encoded protein is a subfamily B receptor, a group with two or four extracellular immunoglobulin domains, a transmembrane domain and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). It is expressed on immune cells and is thought to control inflammatory responses and cytotoxicity. Multiple transcript variants encoding different isoforms have been reported. HGNC lists it among the CD molecules and the inhibitory leukocyte immunoglobulin like receptors.
LILRB1 transduces negative signals on binding MHC class I molecules, making it relevant to studies of how immune responses are restrained.
Engagement of LILRB1 on natural killer cells or T-cells by class I MHC protects target cells from lysis.
Interaction with peptide-bound HLA-G-B2M complex triggers secretion of growth-promoting factors by decidual NK cells.
LILRB1 is a receptor for H301/UL18, a human cytomegalovirus class I MHC homologue, linking it to virus-host interaction research.
LILRB1 is an inhibitory receptor for class I MHC molecules including HLA-A, HLA-B, HLA-C, HLA-G and HLA-F. Ligand binding down-regulates immune responses, and on natural killer cells and T-cells it protects target cells from lysis. It is thought to limit autoreactivity.
LILRB1 is also known as LIR-1, ILT2, MIR-7, CD85, LIR1, CD85j, PIRB and PIR-B. Its earlier name was leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1. NCBI reports multiple transcript variants encoding different isoforms.
LILRB1 is one of the subfamily B leukocyte immunoglobulin-like receptors, which carry cytoplasmic ITIMs. Related family members include LILRB2, LILRB3, LILRB4 and LILRB5. Its ligands include class I MHC molecules and HLA-G in complex with B2M. Check the datasheet of any product for its validated reactivity.
Other inhibitory leukocyte immunoglobulin-like receptors of the LILRB subfamily with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q8NHL6; product specifications from Assay Genie datasheets.